Is prolonged stem cell mobilization detrimental for hematopoiesis?

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 1111-1113

  Chigaev, Alexandre ^a   Winter, Stuart S ^a,b   Sklar, Larry A ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENOTHIAZINE DERIVATIVE; PLERIXAFOR; THIORIDAZINE; VERY LATE ACTIVATION ANTIGEN 4;

AGRANULOCYTOSIS; ANEMIA; ARTICLE; BLOOD DYSCRASIA; BONE MARROW; BONE MARROW APLASIA; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CELL HOMING; CELL PROLIFERATION; CELL SURVIVAL; GRANULOCYTOPENIA; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; SCHIZOPHRENIA; STEM CELL MOBILIZATION; STEM CELL NICHE; THROMBOCYTOPENIA;

ANTIPSYCHOTIC AGENTS; BONE MARROW; HEMATOPOIESIS; HUMANS; INTEGRIN ALPHA4BETA1; MODELS, BIOLOGICAL; PARAPROTEINEMIAS; PHENOTHIAZINES;

EID: 80755140132     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.09.015     Document Type: Article

References (26)

1. Ericson E., Gebbia M., Heisler L.E., Wildenhain J., Tyers M., Giaever G., et al. Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet 2008, 4:e1000151.
2. Sedky K., Lippmann S. Psychotropic medications and leukopenia. Curr Drug Targets 2006, 7:1191-1194.
3. Chigaev A., Wu Y., Williams D.B., Smagley Y., Sklar L.A. Discovery of very late antigen-4 (VLA-4, {alpha}4{beta}1 integrin) allosteric antagonists. J Biol Chem 2011, 286:5455-5463.
4. Stubner S., Grohmann R., Engel R., Bandelow B., Ludwig W.D., Wagner G., et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004, 37(Suppl. 1):S70-S78.
5. Hall R.L., Smith A.G., Edwards J.G. Haematological safety of antipsychotic drugs. Expert Opin Drug Saf 2003, 2:395-399.
6. Kokai M., Morita Y., Fukuda H., Hatotani N. Immunophenotypic studies on atypical lymphocytes in psychiatric patients. Psychiatry Res 1998, 77:105-112.
7. Fessel W.J., Hirata-Hibi M. Abnormal leukocytes in schizophrenia. Arch Gen Psychiatry 1963, 9:601-613.
8. Rogers D.P., Goldsmith C.A. Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev Neurother 2009, 9:47-54.
9. Patterson P.H. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009, 204:313-321.
10. Fieve R.R., Blumenthal B., Little B. The relationship of atypical lymphocytes, phenothiazines, and schizophrenia. Arch Gen Psychiatry 1966, 15:529-534.
11. Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002, 30:973-981.
12. Winkler I.G., Levesque J.P. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol 2006, 34:996-1009.
13. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
14. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004, 18:1-10.
15. Oostendorp R.A., Dormer P. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Leuk Lymphoma 1997, 24:423-435.
16. Coulombel L., Auffray I., Gaugler M.H., Rosemblatt M. Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol 1997, 97:13-21.
17. Bonig H., Wundes A., Chang K.H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008, 111:3439-3441.
18. Zohren F., Toutzaris D., Klarner V., Hartung H.P., Kieseier B., Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008, 111:3893-3895.
19. Papayannopoulou T., Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993, 90:9374-9378.
20. Bonig H., Watts K.L., Chang K.H., Kiem H.P., Papayannopoulou T. Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 2009, 27:836-837.
21. Ramirez P., Rettig M.P., Uy G.L., Deych E., Holt M.S., Ritchey J.K., et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
22. Cashen A.F., Nervi B., DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007, 3:19-27.
23. Hall B.M., Gibson L.F. Regulation of lymphoid and myeloid leukemic cell survival: role of stromal cell adhesion molecules. Leuk Lymphoma 2004, 45:35-48.
24. Carlesso N., Cardoso A.A. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol 2010, 17:281-286.
25. Lindvall O., Kokaia Z., Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004, 10(Suppl.):S42-S50.
26. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.